In the training set (220 HCC and 220 NC), the levels of these nine TAAbs were significantly higher in HCC patients than those in NC, except anti‐CRLF3 (Figs S1b and S2a). This evidence concerns the gene CRLF3 and hepatocellular carcinoma.